

Press release
Lund 17 AUG 2020

Vetiqure AB is now a registered and approved subsidiary of Scandinavian ChemoTech AB

As an important step in the launch of tumour specific electroporation for the veterinary market, the company Vetiqure AB has today been registered and is a wholly owned subsidiary of Scandinavian ChemoTech.

It is gratifying that we can now begin the journey with Vetiqure AB and apply our broad know-how in tumour specific electroporation also in the veterinary market.

For more information, please contact:
Mohan Frick, CEO

+46 (0)10-218 93 00
info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: info@penser.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se